Olusegun I Alatise1, Gregory C Knapp2,3, Brendan Bebington4, Patrick Ayodeji5, Anna Dare3, Jeremy Constable3, Olalekan Olasehinde5, T Peter Kingham3. 1. Department of Surgery, College of Health Sciences, Obafemi Awolowo University Teaching Hospital Complex, PMB 5538, Ile-Ife, Osun State, Nigeria. segunalatishe@yahoo.co.uk. 2. Division of General Surgery, Department of Surgery, Dalhousie University, Halifax, NS, Canada. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Surgery, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 5. Department of Surgery, College of Health Sciences, Obafemi Awolowo University Teaching Hospital Complex, PMB 5538, Ile-Ife, Osun State, Nigeria.
Abstract
INTRODUCTION: There are significant differences in the phenotype of CRC by race in the U.S. A similar CRC phenotype-race relationship also appears to exist in South Africa (SA). However, there is a paucity of comparative data on the presentation and survival of CRC in sub-Saharan African by country of origin or race. This study compares clinicopathologic variables between CRC patients in Nigeria and SA. METHODS: From a prospective CRC database, consecutive patients diagnosed between September, 2013 and October, 2018 from the African Research Group for Oncology in South West Nigeria were compared to consecutive patients diagnosed from January, 2016 to October, 2018 from the Colorectal Cancer in South Africa database. Patients with histologically confirmed adenocarcinoma were included. Patients were excluded if they had in-situ disease or no histological diagnosis. Clinical outcomes were calculated from the date of presentation. National census categories were used to define self-reported race in SA. RESULTS: The mean age at presentation in Nigeria (n = 347) was 54.1 years (SD 15.5) compared to 56.8 (SD 13.7) in SA (n = 534). The median age among Black SA (BSA) patients was significantly lower than the median age among White SA (WSA) patients (55 vs. 63, p < 0.001). Right-sided colon cancer was more common in Nigerian (27.4%) and BSA (21.2%) patients compared to WSA patients (15.2%, p < 0.001). Nigerian (39.1%) and BSA (16.7%) patients were also more likely to present with mucinous histology than WSA patients (4.9%, p < 0.001). There was a significant difference in the stage-at-presentation between the cohorts, with a large burden of stage IV disease in the Nigerian cohort (52.6%). Adjusting for stage-at-presentation, there was a significant difference in the median overall survival between country and racial cohorts. CONCLUSION: There are significant differences in the phenotype of CRC between Nigeria and SA. Nigerian and BSA patients, appear to share characteristics that are different than those of WSA patients. Larger series with tissue banking and next-generation sequencing are needed to better delineate these observed differences.
INTRODUCTION: There are significant differences in the phenotype of CRC by race in the U.S. A similar CRC phenotype-race relationship also appears to exist in South Africa (SA). However, there is a paucity of comparative data on the presentation and survival of CRC in sub-Saharan African by country of origin or race. This study compares clinicopathologic variables between CRC patients in Nigeria and SA. METHODS: From a prospective CRC database, consecutive patients diagnosed between September, 2013 and October, 2018 from the African Research Group for Oncology in South West Nigeria were compared to consecutive patients diagnosed from January, 2016 to October, 2018 from the Colorectal Cancer in South Africa database. Patients with histologically confirmed adenocarcinoma were included. Patients were excluded if they had in-situ disease or no histological diagnosis. Clinical outcomes were calculated from the date of presentation. National census categories were used to define self-reported race in SA. RESULTS: The mean age at presentation in Nigeria (n = 347) was 54.1 years (SD 15.5) compared to 56.8 (SD 13.7) in SA (n = 534). The median age among Black SA (BSA) patients was significantly lower than the median age among White SA (WSA) patients (55 vs. 63, p < 0.001). Right-sided colon cancer was more common in Nigerian (27.4%) and BSA (21.2%) patients compared to WSA patients (15.2%, p < 0.001). Nigerian (39.1%) and BSA (16.7%) patients were also more likely to present with mucinous histology than WSA patients (4.9%, p < 0.001). There was a significant difference in the stage-at-presentation between the cohorts, with a large burden of stage IV disease in the Nigerian cohort (52.6%). Adjusting for stage-at-presentation, there was a significant difference in the median overall survival between country and racial cohorts. CONCLUSION: There are significant differences in the phenotype of CRC between Nigeria and SA. Nigerian and BSA patients, appear to share characteristics that are different than those of WSA patients. Larger series with tissue banking and next-generation sequencing are needed to better delineate these observed differences.
Authors: David O Irabor; Olayiwola A Oluwasola; Olufemi J Ogunbiyi; Olabiyi G Ogun; Clement A Okolo; Marilena Melas; Stephen B Gruber; Chanjuan Shi; Leon Raskin Journal: Anticancer Res Date: 2017-05 Impact factor: 2.480
Authors: Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: Yinzhi Lai; Chun Wang; Jesse M Civan; Juan P Palazzo; Zhong Ye; Terry Hyslop; Jianqing Lin; Ronald E Myers; Bingshan Li; Binghua Jiang; Ashwin Sama; Jinliang Xing; Hushan Yang Journal: Gastroenterology Date: 2016-02-02 Impact factor: 22.682
Authors: Luisa N Borrell; Jennifer R Elhawary; Elena Fuentes-Afflick; Jonathan Witonsky; Nirav Bhakta; Alan H B Wu; Kirsten Bibbins-Domingo; José R Rodríguez-Santana; Michael A Lenoir; James R Gavin; Rick A Kittles; Noah A Zaitlen; David S Wilkes; Neil R Powe; Elad Ziv; Esteban G Burchard Journal: N Engl J Med Date: 2021-01-06 Impact factor: 91.245